Equities analysts predict that Fennec Pharmaceuticals Inc (NASDAQ:FENC) will post earnings of ($0.24) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Fennec Pharmaceuticals’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.26). Fennec Pharmaceuticals posted earnings per share of ($0.14) during the same quarter last year, which suggests a negative year over year growth rate of 71.4%. The business is scheduled to report its next earnings report on Tuesday, November 12th.
On average, analysts expect that Fennec Pharmaceuticals will report full year earnings of ($0.85) per share for the current year, with EPS estimates ranging from ($0.92) to ($0.77). For the next year, analysts expect that the business will report earnings of $1.21 per share, with EPS estimates ranging from ($0.52) to $2.94. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Fennec Pharmaceuticals.
Fennec Pharmaceuticals (NASDAQ:FENC) last released its earnings results on Friday, August 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.10).
NASDAQ:FENC opened at $4.56 on Tuesday. The company has a market cap of $90.72 million, a PE ratio of -9.12 and a beta of 0.08. Fennec Pharmaceuticals has a twelve month low of $3.26 and a twelve month high of $8.23. The company’s 50 day moving average is $4.64 and its two-hundred day moving average is $4.32.
Several hedge funds have recently added to or reduced their stakes in the company. United Services Automobile Association boosted its holdings in shares of Fennec Pharmaceuticals by 32.1% in the 2nd quarter. United Services Automobile Association now owns 229,983 shares of the company’s stock valued at $920,000 after acquiring an additional 55,933 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Fennec Pharmaceuticals in the 2nd quarter valued at $218,000. Hartford Financial Management Inc. boosted its holdings in shares of Fennec Pharmaceuticals by 65.0% in the 2nd quarter. Hartford Financial Management Inc. now owns 20,300 shares of the company’s stock valued at $81,000 after acquiring an additional 8,000 shares during the last quarter. Atria Investments LLC purchased a new stake in shares of Fennec Pharmaceuticals in the 2nd quarter valued at $215,000. Finally, Wedbush Securities Inc. purchased a new stake in shares of Fennec Pharmaceuticals in the 3rd quarter valued at $57,000. 45.28% of the stock is currently owned by institutional investors and hedge funds.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Article: What type of investment options does a Roth IRA provide?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.